Kunihiko Matsui

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4191465/publications.pdf

Version: 2024-02-01

72 papers

1,785 citations

471509 17 h-index 289244 40 g-index

72 all docs 72 docs citations

72 times ranked 2835 citing authors

#	Article	IF	CITATIONS
1	Optimal uric acid levels by febuxostat treatment and cerebral, cardiorenovascular risks: <i>post hoc</i> analysis of a randomized controlled trial. Rheumatology, 2022, 61, 2346-2359.	1.9	9
2	Effect of febuxostat on clinical outcomes in patients with hyperuricemia and cardiovascular disease. International Journal of Cardiology, 2022, 349, 127-133.	1.7	14
3	Rationale and Design of the Efficacy and Safety of Esaxerenone in Hypertensive Patients With Left Ventricular Hypertrophy (ESES-LVH) Study ― Protocol for a Multicenter, Open-Label, Exploratory Interventional Study ―. Circulation Reports, 2022, 4, 99-104.	1.0	2
4	The impact of kidney function in patients on antithrombotic therapy: a post hoc subgroup analysis focusing on recurrent bleeding events from the AFIRE trial. BMC Medicine, 2022, 20, 69.	5 . 5	0
5	Rivaroxaban Underdose for Atrial Fibrillation with Stable Coronary Disease: The AFIRE Trial Findings. Thrombosis and Haemostasis, 2022, 122, 1584-1593.	3.4	5
6	Rivaroxaban Monotherapy vs Combination Therapy With Antiplatelets on Total Thrombotic and Bleeding Events in Atrial Fibrillation With Stable Coronary Artery Disease. JAMA Cardiology, 2022, 7, 787.	6.1	7
7	Risk of serious infection, malignancy, or death in Japanese rheumatoid arthritis patients treated with a combination of abatacept and tacrolimus: a retrospective cohort study. Clinical Rheumatology, 2021, 40, 1811-1817.	2.2	2
8	Effects of Statin Plus Ezetimibe on Coronary Plaques in Acute Coronary Syndrome Patients with Diabetes Mellitus: Sub-Analysis of PRECISE-IVUS Trial. Journal of Atherosclerosis and Thrombosis, 2021, 28, 181-193.	2.0	6
9	Fine particulate matter and out-of-hospital cardiac arrest of respiratory origin. European Respiratory Journal, 2021, 57, 2004299.	6.7	3
10	Rivaroxaban monotherapy versus combination therapy according to patient risk of stroke and bleeding in atrial fibrillation and stable coronary disease: AFIRE trial subanalysis. American Heart Journal, 2021, 236, 59-68.	2.7	7
11	Aspirin versus P2Y ₁₂ inhibitors with anticoagulation therapy for atrial fibrillation. Heart, 2021, 107, 1731-1738.	2.9	2
12	Bleeding and Subsequent Cardiovascular Events and Death in Atrial Fibrillation With Stable Coronary Artery Disease: Insights From the AFIRE Trial. Circulation: Cardiovascular Interventions, 2021, 14, e010476.	3.9	20
13	Vaccination Hesitancy for COVID-19. JMA Journal, 2021, 4, 443-444.	0.8	O
14	Clinical Outcomes of Rivaroxaban Monotherapy in Heart Failure Patients With Atrial Fibrillation and Stable Coronary Disease: Insights From the AFIRE Trial. Circulation, 2021, 144, 1449-1451.	1.6	3
15	Rivaroxaban Monotherapy in Patients With Atrial Fibrillation After Coronary Stenting. JACC: Cardiovascular Interventions, 2021, 14, 2330-2340.	2.9	13
16	Reduction in hsCRP levels is associated with decreased incidence of cardiovascular events in Japanese hypertensive women but not in men. Scientific Reports, 2020, 10, 17040.	3.3	7
17	Cognitive function in post-cardiac intensive care: patient characteristics and impact of multidisciplinary cardiac rehabilitation. Heart and Vessels, 2020, 35, 946-956.	1.2	7
18	Associations between corrected serum calcium and phosphorus levels and outcome in dialysis patients in the Kumamoto Prefecture. Hemodialysis International, 2020, 24, 202-211.	0.9	8

#	Article	IF	CITATIONS
19	H 2 FPEF score for predicting future heart failure in stable outpatients with cardiovascular risk factors. ESC Heart Failure, 2020, 7, 66-75.	3.1	16
20	Association of Fine Particulate Matter Exposure With Bystander-Witnessed Out-of-Hospital Cardiac Arrest of Cardiac Origin in Japan. JAMA Network Open, 2020, 3, e203043.	5.9	16
21	Total adiponectin is associated with incident cardiovascular and renal events in treated hypertensive patients: subanalysis of the ATTEMPT-CVD randomized trial. Scientific Reports, 2019, 9, 16589.	3.3	12
22	Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease. New England Journal of Medicine, 2019, 381, 1103-1113.	27.0	342
23	Anemia is an independent risk factor for cardiovascular and renal events in hypertensive outpatients with well-controlled blood pressure: a subgroup analysis of the ATTEMPT-CVD randomized trial. Hypertension Research, 2019, 42, 883-891.	2.7	12
24	Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy. European Heart Journal, 2019, 40, 1778-1786.	2.2	148
25	A retrospective study of arterial stiffness and subsequent clinical outcomes in cancer patients undergoing percutaneous coronary intervention. Journal of Hypertension, 2019, 37, 754-764.	0.5	17
26	Differential predictive factors for cardiovascular events in patients with or without cancer history. Medicine (United States), 2019, 98, e17602.	1.0	15
27	Cardiovascular and renal protective role of angiotensin blockade in hypertension with advanced CKD: a subgroup analysis of ATTEMPT-CVD randomized trial. Scientific Reports, 2018, 8, 3150.	3.3	5
28	Atrial fibrillation and ischemic events with rivaroxaban in patients with stable coronary artery disease (AFIRE): Protocol for a multicenter, prospective, randomized, open-label, parallel group study. International Journal of Cardiology, 2018, 265, 108-112.	1.7	24
29	Study on the Effect of Irbesartan on Atrial Fibrillation Recurrence in Kumamoto: Atrial Fibrillation Suppression Trial (SILK study). Journal of Cardiology, 2018, 71, 129-134.	1.9	7
30	Two cases of numb chin syndrome diagnosed as malignant disease. Oxford Medical Case Reports, 2018, 2018, omy097.	0.4	5
31	Tailored Adjunctive Cilostazol Therapy Based on CYP2C19 Genotyping in Patients With Acute Myocardial Infarction ― The CALDERA-GENE Study ―. Circulation Journal, 2018, 82, 1517-1525.	1.6	9
32	Impact of statin-ezetimibe combination on coronary atheroma plaque in patients with and without chronic kidney disease â€" Sub-analysis of PRECISE-IVUS trial. International Journal of Cardiology, 2018, 268, 23-26.	1.7	5
33	Baseline serum sitosterol level as predictor of adverse clinical eventsÂin acute coronary syndrome patients with dyslipidaemia: AÂsub-analysis of HIJ-PROPER. Atherosclerosis, 2018, 274, 139-145.	0.8	28
34	Clinical outcomes of percutaneous coronary intervention for acute coronary syndrome between hospitals with and without onsite cardiac surgery backup. Journal of Cardiology, 2017, 69, 103-109.	1.9	4
35	Rationale, design, and baseline characteristics of a study to evaluate the effect of febuxostat in preventing cerebral, cardiovascular, and renal events in patients with hyperuricemia. Journal of Cardiology, 2017, 69, 169-175.	1.9	40
36	Renal Denervation in the Acute Phase of Ischemic Stroke Provides Brain Protection in Hypertensive Rats. Stroke, 2017, 48, 1104-1107.	2.0	11

3

#	Article	IF	CITATIONS
37	Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial. European Heart Journal, 2017, 38, 2264-2276.	2.2	94
38	Effects of the Mean Amplitude of Glycemic Excursions and Vascular Endothelial Dysfunction on Cardiovascular Events in Nondiabetic Patients With Coronary Artery Disease. Journal of the American Heart Association, 2017, 6, .	3.7	21
	Study design of GENERAL (general practitioners and embolism prevention in NVAF patients treated with) Tj ETQq	1 1 0.784	314 rgBT /O
39	investigate the effectiveness and safety of rivaroxaban in Japanese patients with NVAF. Journal of Arrhythmia. 2017. 33. 297-301.	1.2	2
40	Prognostic Value of the CHADS ₂ Score for Adverse Cardiovascular Events in Coronary Artery Disease Patients Without Atrial Fibrillationâ€"A Multiâ€Center Observational Cohort Study. Journal of the American Heart Association, 2017, 6, .	3.7	17
41	Rationale, design features, and baseline characteristics: The Heart Institute of Japan-PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ-PROPER). Journal of Cardiology, 2017, 69, 536-541.	1.9	9
42	Transient Mild Cerebral Ischemia Significantly Deteriorated Cognitive Impairment in a Mouse Model of Alzheimer's Disease <i>via</i> Angiotensin AT1 Receptor. American Journal of Hypertension, 2017, 30, 141-150.	2.0	28
43	Asian dust exposure triggers acute myocardial infarction. European Heart Journal, 2017, 38, 3202-3208.	2.2	43
44	Association of CYP2C19 variants and epoxyeicosatrienoic acids on patients with microvascular angina. American Journal of Physiology - Heart and Circulatory Physiology, 2016, 311, H1409-H1415.	3.2	12
45	Impaired Peripheral Endothelial Function Assessed by Digital Reactive Hyperemia Peripheral Arterial Tonometry and Risk of Inâ€ S tent Restenosis. Journal of the American Heart Association, 2016, 5, .	3.7	8
46	Impact of Statin Therapy on Clinical Outcome in Patients With Coronary Spasm. Journal of the American Heart Association, 2016, 5 , .	3.7	51
47	Prevalence of coronary macro- and micro-vascular dysfunctions after drug-eluting stent implantation without in-stent restenosis. International Journal of Cardiology, 2016, 222, 185-194.	1.7	16
48	Changes in the risk factors for coronary spasm. IJC Heart and Vasculature, 2016, 12, 85-87.	1.1	4
49	Impact of aspirin on the prognosis in patients with coronary spasm without significant atherosclerotic stenosis. International Journal of Cardiology, 2016, 220, 328-332.	1.7	26
50	Lipid profile associated with coronary plaque regression in patients with acute coronary syndrome: Subanalysis of PRECISE-IVUS trial. Atherosclerosis, 2016, 251, 367-372.	0.8	22
51	Synergistic effect of ezetimibe addition on coronary atheroma regression in patients with prior statin therapy: Subanalysis of PRECISE-IVUS trial. European Journal of Preventive Cardiology, 2016, 23, 1524-1528.	1.8	12
52	Patients with both CYP2C19 loss-of-function allele and peripheral endothelial dysfunction are significantly correlated with adverse cardiovascular events following coronary stent implantation. Journal of Cardiology, 2016, 67, 104-109.	1.9	9
53	Impact of candesartan on cardiovascular events after drug-eluting stent implantation in patients with coronary artery disease: The 4C trial. Journal of Cardiology, 2016, 67, 371-377.	1.9	3
54	A trial of telmisartan prevention of cardiovascular diseases (ATTEMPT-CVD): Biomarker study. European Journal of Preventive Cardiology, 2016, 23, 913-921.	1.8	12

#	Article	IF	CITATIONS
55	Liraglutide, a Glucagon-Like Peptide-1 Analog, Increased Insulin Sensitivity Assessed by Hyperinsulinemic-Euglycemic Clamp Examination in Patients with Uncontrolled Type 2 Diabetes Mellitus. Journal of Diabetes Research, 2015, 2015, 1-8.	2.3	40
56	A pilot study of ezetimibe vs. atorvastatin for improving peripheral microvascular endothelial function in stable patients with type 2 diabetes mellitus. Lipids in Health and Disease, 2015, 14, 37.	3.0	10
57	Determinants of Myocardial Lactate Production During Acetylcholine Provocation Test in Patients With Coronary Spasm. Journal of the American Heart Association, 2015, 4, .	3.7	8
58	Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2015, 66, 495-507.	2.8	352
59	Remitting seronegative symmetrical synovitis with pitting edema syndrome in individuals with type 2 diabetes mellitus or impaired glucose tolerance. Diabetes Research and Clinical Practice, 2015, 110, e5-e8.	2.8	14
60	Acetylcholine-Provoked Coronary Spasm at Site of Significant Organic Stenosis Predicts Poor Prognosis in Patients With Coronary Vasospastic Angina. Journal of the American College of Cardiology, 2015, 66, 1105-1115.	2.8	59
61	Differential effectiveness of ARB plus CCB therapy and high-dose ARB therapy in high-risk elderly hypertensive patients: Subanalysis of the OSCAR study. Hypertension Research, 2015, 38, 199-207.	2.7	5
62	Incremental Prognostic Significance of the Elevated Levels of Pentraxin 3 in Patients With Heart Failure With Normal Left Ventricular Ejection Fraction. Journal of the American Heart Association, 2014, 3, .	3.7	24
63	Chronic kidney disease status modifies the association of CYP2C19 polymorphism in predicting clinical outcomes following coronary stent implantation. Thrombosis Research, 2014, 134, 939-944.	1.7	18
64	Clinical outcomes of percutaneous coronary intervention (PCI) at hospital with or without onsite cardiac surgery backup. International Journal of Cardiology, 2014, 176, 1385-1387.	1.7	2
65	Current Status and Issues in Offering a Course on Introductory Medicine as Preparatory Education for First Year Undergraduate Medical Students. Yamaguchi Medical Journal, 2014, 63, 269-273.	0.1	1
66	Current Status and Issues of Practical Training in Welfare Facilities for the Elderly as an Early Exposure for Medical Students Yamaguchi Medical Journal, 2014, 63, 263-267.	0.1	0
67	Quality of ambulatory care provided by physicians-in-training for common diseases before and after the Japanese government reformed post-graduate medical education. Tenri Medical Bulletin, 2012, 15, 25-33.	0.1	0
68	Reply to Letter Regarding Article, "Weekend Onset of Acute Myocardial Infarction Does Not Have a Negative Impact on Outcome in Japan". Circulation Journal, 2008, 72, 865.	1.6	0
69	Weekend Onset of Acute Myocardial Infarction Does Not Have a Negative Impact on Outcome in Japan. Circulation Journal, 2007, 71, 1841-1844.	1.6	30
70	What are ^ ^ldquo;Generalists^ ^rdquo;? Social Expectations and Future Directions for Generalist Physicians. General Medicine, 2007, 8, 3-4.	0.1	1
71	Medications Prescribed at Discharge for Patients with Acute Myocardial Infarction : Evidence-to-Practice Gap in Janan. General Medicine, 2007, 8, 13-18.	0.1	0
72	C-reactive Protein Levels and Cardiovascular Outcomes After Febuxostat Treatment in Patients with Asymptomatic Hyperuricemia: Post-hoc Analysis of a Randomized Controlled Study. Cardiovascular Drugs and Therapy, 0, , .	2.6	1